soul trial oral semaglutide cardiovascular outcomes 2024 nejm ๐งฟ is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Semaglutide and Cardiovascular Outcomes in
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 9 - Aug 14







/product/83/132086/1.jpg?5466)




















